Please login to order a test.
Hepatitis B Surface Antibody, Quantitative, HBIG Assessment
- Antibody to Hepatitis B Surface Antigen
Endpoint determination of HBsAb
This test is designed for use in assessing therapy with HBIG for patients who have had a liver transplant.
Presence of anti-HBs is not an absolute indicator of resolved hepatitis infection nor of protection from future infection. Since there are different serologic subtypes of hepatitis B virus, it is possible (and has been reported) for a patient to have antibody to one surface antigen type and to be acutely infected with a virus of a different subtype. Thus, a patient may have coexisting HBsAg and anti-HBs. Transfused individuals or hemophiliacs receiving plasma components may have false-positive results for antibody to hepatitis B surface antigen.
Immunochemiluminometric assay (ICMA). Samples will be diluted and titered to endpoint.
Serum or plasma
0.5 mL (Note: This volume does not allow for repeat testing.)
Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|144072||HBsAb Quant HBIG Assessment||144073||HBsAb Quant HBIG Assessment||mIU/mL||16935-9|